CL2020002573A1 - Inhibidores atf6 y sus usos. - Google Patents
Inhibidores atf6 y sus usos.Info
- Publication number
- CL2020002573A1 CL2020002573A1 CL2020002573A CL2020002573A CL2020002573A1 CL 2020002573 A1 CL2020002573 A1 CL 2020002573A1 CL 2020002573 A CL2020002573 A CL 2020002573A CL 2020002573 A CL2020002573 A CL 2020002573A CL 2020002573 A1 CL2020002573 A1 CL 2020002573A1
- Authority
- CL
- Chile
- Prior art keywords
- atf6
- inhibitors
- compounds
- diseases
- treating
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150014641 Atf6 gene Proteins 0.000 title 1
- 102000007481 Activating Transcription Factor 6 Human genes 0.000 abstract 3
- 108010085405 Activating Transcription Factor 6 Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 201000011531 vascular cancer Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Se proporcionan compuestos como inhibidores del factor de transcripción activador 6 (ATF6). Los compuestos pueden ser útiles como agentes terapéuticos para tratar enfermedades o trastornos mediados por ATF6 y pueden ser particularmente útiles para tratar infecciones virales, enfermedades neurodegenerativas, enfermedades vasculares o cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862654263P | 2018-04-06 | 2018-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002573A1 true CL2020002573A1 (es) | 2021-03-05 |
Family
ID=66248737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002573A CL2020002573A1 (es) | 2018-04-06 | 2020-10-05 | Inhibidores atf6 y sus usos. |
Country Status (14)
Country | Link |
---|---|
US (3) | US10829485B2 (es) |
EP (1) | EP3774782A2 (es) |
JP (1) | JP7476167B2 (es) |
KR (1) | KR20210028144A (es) |
CN (1) | CN112313224A (es) |
AU (1) | AU2019247533B2 (es) |
BR (1) | BR112020020181A2 (es) |
CA (1) | CA3096139A1 (es) |
CL (1) | CL2020002573A1 (es) |
IL (1) | IL277794B2 (es) |
MX (1) | MX2020010469A (es) |
RU (1) | RU2020136310A (es) |
SG (1) | SG11202009570SA (es) |
WO (1) | WO2019195810A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021069721A1 (en) * | 2019-10-09 | 2021-04-15 | Black Belt Tx Ltd | Atf6 modulators and uses thereof |
BR112022006734A2 (pt) * | 2019-10-09 | 2022-09-06 | Praxis Biotech LLC | Moduladores atf6 e usos dos mesmos |
EP4001917A1 (en) | 2020-11-12 | 2022-05-25 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Inhibitors for use in treating liver disorders |
KR102644194B1 (ko) * | 2021-02-22 | 2024-03-08 | 주식회사 이노셀젠헬스케어 | 종양의 진단 및 치료를 위한 표적단백질로서의 atf6 |
WO2022266232A1 (en) * | 2021-06-16 | 2022-12-22 | Sanford Burnham Prebys Medical Discovery Institute | Methods and compositions for treating chronic liver disease and hepatocellular carcinoma |
CN113501787A (zh) * | 2021-08-20 | 2021-10-15 | 黑龙江省科学院石油化学研究院 | 一种合成6-三氟甲基-3-甲基吲唑的方法 |
WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
KR20240030727A (ko) * | 2022-08-31 | 2024-03-07 | 단국대학교 천안캠퍼스 산학협력단 | 퓨릴티아졸계 화합물 및 이를 유효성분으로 포함하는 근감소증 예방 또는 치료용 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1073658B1 (en) * | 1998-04-20 | 2003-08-13 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
GEP20074236B (en) * | 2003-05-01 | 2007-11-12 | Bristol Myers Squibb Co | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
JP2009521430A (ja) | 2005-12-23 | 2009-06-04 | アストラゼネカ・アクチエボラーグ | Gaba−b受容体モジュレーター |
AR069650A1 (es) * | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2010101964A2 (en) * | 2009-03-02 | 2010-09-10 | Stemsynergy Therapeutics, Inc | Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell |
EP2516417B1 (en) | 2009-12-22 | 2017-10-11 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
MX2015001864A (es) | 2012-08-10 | 2015-05-15 | Hoffmann La Roche | Compuestos de pirazol-carboxamida, composiciones y metodos de uso. |
EP2903611A4 (en) * | 2012-10-04 | 2016-11-16 | Oyagen Inc | SMALL MOLECULES AS ANTI-HIV AGENTS FOR INTERRUPTING THE VIF SELF-ASSOCIATION AND METHOD FOR USE THEREOF |
LT3286181T (lt) * | 2015-04-22 | 2021-04-26 | Rigel Pharmaceuticals, Inc. | Pirazolo junginiai ir junginių gamybos bei naudojimo būdas |
AU2016284398C1 (en) | 2015-06-22 | 2021-01-07 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
SI3390395T1 (sl) | 2015-12-16 | 2020-11-30 | Loxo Oncology, Inc. | Spojine uporabne kot inhibitorji kinaz |
US10898469B2 (en) | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
US10357477B2 (en) | 2016-09-13 | 2019-07-23 | Regents Of The University Of Minnesota | Anticancer compounds |
-
2019
- 2019-04-06 US US16/377,156 patent/US10829485B2/en active Active
- 2019-04-06 SG SG11202009570SA patent/SG11202009570SA/en unknown
- 2019-04-06 MX MX2020010469A patent/MX2020010469A/es unknown
- 2019-04-06 CA CA3096139A patent/CA3096139A1/en active Pending
- 2019-04-06 EP EP19719005.1A patent/EP3774782A2/en active Pending
- 2019-04-06 BR BR112020020181-2A patent/BR112020020181A2/pt not_active Application Discontinuation
- 2019-04-06 CN CN201980037115.9A patent/CN112313224A/zh active Pending
- 2019-04-06 KR KR1020207031697A patent/KR20210028144A/ko unknown
- 2019-04-06 AU AU2019247533A patent/AU2019247533B2/en active Active
- 2019-04-06 WO PCT/US2019/026198 patent/WO2019195810A2/en active Application Filing
- 2019-04-06 JP JP2021504139A patent/JP7476167B2/ja active Active
- 2019-04-06 IL IL277794A patent/IL277794B2/en unknown
- 2019-04-06 RU RU2020136310A patent/RU2020136310A/ru unknown
-
2020
- 2020-08-12 US US16/992,000 patent/US20210221803A1/en not_active Abandoned
- 2020-10-05 CL CL2020002573A patent/CL2020002573A1/es unknown
-
2023
- 2023-05-26 US US18/324,826 patent/US20240124434A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL277794B1 (en) | 2023-10-01 |
CA3096139A1 (en) | 2019-10-10 |
US20190367497A1 (en) | 2019-12-05 |
RU2020136310A (ru) | 2022-05-06 |
AU2019247533B2 (en) | 2023-09-28 |
MX2020010469A (es) | 2021-04-19 |
SG11202009570SA (en) | 2020-10-29 |
JP7476167B2 (ja) | 2024-04-30 |
CN112313224A (zh) | 2021-02-02 |
US20210221803A1 (en) | 2021-07-22 |
JP2021521271A (ja) | 2021-08-26 |
IL277794B2 (en) | 2024-02-01 |
KR20210028144A (ko) | 2021-03-11 |
IL277794A (en) | 2020-11-30 |
RU2020136310A3 (es) | 2022-05-06 |
WO2019195810A3 (en) | 2019-11-21 |
EP3774782A2 (en) | 2021-02-17 |
WO2019195810A2 (en) | 2019-10-10 |
US10829485B2 (en) | 2020-11-10 |
AU2019247533A1 (en) | 2020-10-15 |
BR112020020181A2 (pt) | 2021-01-19 |
US20240124434A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2021000151A2 (es) | Inhibidores de pd-1/pd-l1 | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
ECSP18073726A (es) | Inhibidores del enlace proteína-proteína de wdr5 | |
SV2017005557A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
BR112017012342A2 (pt) | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos | |
MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
CL2019000304A1 (es) | Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento. | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
CR20180493A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
ECSP21026485A (es) | Piridazinonas y sus métodos de uso | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CL2018003109A1 (es) | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. |